181

(6)(3)

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

PUBLIC HEALTH SERVICE

National Institute of Mental Health
Addiction Research Center
U.S. Public Health Service Hospital
Lexington, Kentucky

19 October 1960

(6)(3)

In accordance with Ray's telephone call of October 19th I have the following supplies of the materials on hand:

Agroclavine (V-A-18), 440 mg,

Dihydroagroclavine (V-A-19), 450 mg,

Dihydroergokryptine (V-A-20), 25 mg,

7, 9-Dimethyl-9-hydroxy-4, 5, 5a, 6, 6a, 7, 8, 9-octahydroindolo [4. 3-fg] quinoline (V-A-21, or Lilly 23194), 315 mg,

Elymoclavine (V-A-22), 100 mg.

You may have any or all of these materials since, with the exception of V-A-21, I can get additional supplies from Dr. T. Yui of Takeda, Japan.

We have never studied V-A-20 here. It was sent, without our requesting it, in the hope we would test if for adrenergic blocking properties.

Key reference on numbers V-A-18, 19, 21 and 22 is: Yui, T. and Takeo, Y.: Neuropharmacological studies on a new series of ergot alkaloids, Japanese Journal of Pharmacology, 7: 157-161 (March) 1958. The only information I have on V-A-21 or Lilly 23194 is in the form of thermofax sheets sent me by Dr. Slater of the Lilly Laboratories.

B-326

(b)(3)

They indicate LSD-like effects in cats and rats, but in man this compound had potent hypnotic properties.

Looking forward to seeing you soon,

Very sincerely,

Harris Isbell, M. D.
Director

HI:bws

B-325